Skip to content
10-Q/A

Quarterly Report

SALIX PHARMACEUTICALS LTD

0001193125-15-073236

← back to feed
Filed
Mar 2, 2015 12:00 AM ET
Period of report
Amendment. Amends a previously filed report.
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2014 · May 4, 2014 63.41M sh
Shares Diluted Q1 2014 · Mar 31, 2014 63.32M sh
Shares Diluted Q1 2014 · Mar 31, 2013 63.42M sh
Capex Q1 2014 · Mar 31, 2014 $4.61M
Capex Q1 2014 · Mar 31, 2013 $1.21M
Long Term Debt restated Q1 2014 · Mar 31, 2014 $3.46B
Long Term Debt restated Q1 2014 · Dec 31, 2013 $1.78B
Cash And Equivalents Q1 2014 · Mar 31, 2014 $385.1M
Cash And Equivalents Q1 2014 · Dec 31, 2013 $1.16B
Cash And Equivalents Q1 2014 · Mar 31, 2013 $960.29M
Cash And Equivalents Q1 2014 · Dec 31, 2012 $751.01M
Stockholders Equity restated Q1 2014 · Mar 31, 2014 $708.43M
Stockholders Equity restated Q1 2014 · Dec 31, 2013 $728.64M
Current Liabilities restated Q1 2014 · Mar 31, 2014 $582.43M
Current Liabilities restated Q1 2014 · Dec 31, 2013 $417.24M
Current Assets restated Q1 2014 · Mar 31, 2014 $1.31B
Current Assets restated Q1 2014 · Dec 31, 2013 $2.28B
Total Assets restated Q1 2014 · Mar 31, 2014 $4.75B
Total Assets restated Q1 2014 · Dec 31, 2013 $2.93B
Eps Diluted restated Q1 2014 · Mar 31, 2014 −$0.55
Eps Diluted Q1 2014 · Mar 31, 2013 $0.35
Eps Basic restated Q1 2014 · Mar 31, 2014 −$0.55
Eps Basic Q1 2014 · Mar 31, 2013 $0.37
Sga Expense restated Q1 2014 · Mar 31, 2014 $207.1M
Sga Expense restated Q1 2014 · Mar 31, 2013 $84.98M
Rd Expense restated Q1 2014 · Mar 31, 2014 $41.22M
Rd Expense restated Q1 2014 · Mar 31, 2013 $21.61M
Net Income restated Q1 2014 · Mar 31, 2014 −$34.58M
Net Income Q1 2014 · Mar 31, 2013 $22.44M
Operating Income restated Q1 2014 · Mar 31, 2014 −$20.22M
Operating Income Q1 2014 · Mar 31, 2013 $49.27M
Cost Of Revenue restated Q1 2014 · Mar 31, 2014 $116.94M
Cost Of Revenue Q1 2014 · Mar 31, 2013 $33.07M
Revenue restated Q1 2014 · Mar 31, 2014 $402.98M
Revenue Q1 2014 · Mar 31, 2013 $202.6M